BioNTech SE (BNTX) Financials

NASDAQ:BNTX

Market Cap

26.48B

Total Revenue

17.31B

Gross Profit

12.78B

Operating Income

12.64B

Net Income

9.43B

Metric	2017	2018	2019	2020	2021	2022
revenue	61,598,000	127,575,000	108,589,000	482,325,000	18,976,700,000	17,310,600,000
costOfRevenue	94,814,000	156,730,000	243,827,000	704,362,000	3,860,700,000	4,532,000,000
grossProfit	-33,216,000	-29,155,000	-135,238,000	-222,037,000	15,116,000,000	12,778,600,000
researchAndDevelopmentExpenses	85,496,000	143,040,000	226,466,000	645,029,000	102,700,000	116,000,000
sellingAndMarketingExpenses	6,603,000	3,041,000	2,718,000	14,512,000	50,400,000	59,500,000
generalAndAdministrativeExpenses	22,889,000	24,049,000	40,692,000	94,049,000	278,500,000	484,700,000
sellingGeneralAndAdministrativeExpenses	29,492,000	27,090,000	43,410,000	108,561,000	328,900,000	544,200,000
operatingExpenses	28,061,000	24,698,000	46,280,000	-139,620,000	200,100,000	135,900,000
operatingIncome	-61,277,000	-53,854,000	-181,518,000	-82,417,000	15,283,800,000	12,642,700,000
totalOtherIncomeExpensesNet	-26,033,000	5,966,000	2,078,000	-63,385,000	-237,400,000	311,400,000
ebitda	-48,745,000	-30,007,000	-146,167,000	-42,109,000	14,970,700,000	13,096,300,000
depreciationAndAmortization	10,529,000	21,984,000	35,351,000	40,308,000	-313,100,000	453,600,000
interestIncome	2,133,000	1,996,000	1,781,000	1,564,000	1,500,000	330,300,000
interestExpense	676,000	1,721,000	1,718,000	64,949,000	5,400,000	18,900,000
incomeBeforeTax	-85,905,000	-47,662,000	-179,440,000	-145,802,000	15,046,400,000	12,954,100,000
incomeTaxExpense	45,000	600,000	-268,000	-161,000,000	4,753,900,000	3,519,700,000
netIncome	-85,653,000	-48,019,000	-179,172,000	15,198,000	10,292,500,000	9,434,400,000
eps	-0.38	-0.21	-0.85	0.06	42.18	38.78
epsdiluted	-0.38	-0.21	-0.85	0.06	39.63	37.77
weightedAverageShsOut	226,859,216	226,859,216	211,500,000	253,300,000	244,000,000	243,280,041
weightedAverageShsOutDil	226,859,216	226,859,216	211,500,000	253,300,000	259,700,000	249,785,544
costAndExpenses	122,875,000	181,428,000	290,107,000	564,742,000	4,060,800,000	4,667,900,000
otherExpenses	--	--	-223,596,000	-893,210,000	-128,800,000	-524,300,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Mainz, , DE

Website

biontech.de

CEO

Prof. Ugur Sahin M.D.

Employees

5500

About the Company

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.